IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Abstract Although chimeric antigen receptor (CAR)-engineered T cells have shown great success in the treatment of B cell malignancies, this strategy has limited efficacy in patients with solid tumors. In mouse CAR-T cells, IL-7 and CCL19 expression have been demonstrated to improve T cell infiltrati...

詳細記述

書誌詳細

主要な著者:	Nengzhi Pang, Jingxuan Shi, Le Qin, Aiming Chen, Yuou Tang, Hainan Yang, Yufeng Huang, Qingde Wu, Xufeng Li, Bingjia He, Tianheng Li, Baoxia Liang, Jinglin Zhang, Bihui Cao, Manting Liu, Yunfei Feng, Xiaodie Ye, Xiaopei Chen, Lu Wang, Yu Tian, Hao Li, Junping Li, Hong Hu, Jingping He, Yuling Hu, Cheng Zhi, Zhaoyang Tang, Yibo Gong, Fangting Xu, Linfeng Xu, Weijun Fan, Ming Zhao, Deji Chen, Hui Lian, Lili Yang, Peng Li, Zhenfeng Zhang
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2021-07-01
シリーズ:	Journal of Hematology & Oncology
主題:	CAR-T cell IL-7 CCL19 Glypican-3 Mesothelin Pancreatic carcinoma
オンライン･アクセス:	https://doi.org/10.1186/s13045-021-01128-9
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!